132 related articles for article (PubMed ID: 34082612)
1. Quantifying Proximal Collecting Tubule Deficiency in Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Fetopathy.
Saunders J; Callejas Salgado AM; Ting JY; Mammen C; Terry J; Bush JW
Pediatr Dev Pathol; 2021; 24(5):438-444. PubMed ID: 34082612
[TBL] [Abstract][Full Text] [Related]
2. Fetotoxic risk of AT1 blockers exceeds that of angiotensin-converting enzyme inhibitors: an observational study.
Weber-Schoendorfer C; Kayser A; Tissen-Diabaté T; Winterfeld U; Eleftheriou G; Te Winkel B; Diav-Citrin O; Greenall A; Hoeltzenbein M; Schaefer C
J Hypertens; 2020 Jan; 38(1):133-141. PubMed ID: 31568057
[TBL] [Abstract][Full Text] [Related]
3. Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists.
Quan A
Early Hum Dev; 2006 Jan; 82(1):23-8. PubMed ID: 16427219
[TBL] [Abstract][Full Text] [Related]
4. ACE inhibitor fetopathy and hypocalvaria: the kidney-skull connection.
Barr M; Cohen MM
Teratology; 1991 Nov; 44(5):485-95. PubMed ID: 1771591
[TBL] [Abstract][Full Text] [Related]
5. Recognition and management of angiotensin converting enzyme inhibitor fetopathy.
Sedman AB; Kershaw DB; Bunchman TE
Pediatr Nephrol; 1995 Jun; 9(3):382-5. PubMed ID: 7632538
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin-converting enzyme inhibitor fetopathy.
Pryde PG; Sedman AB; Nugent CE; Barr M
J Am Soc Nephrol; 1993 Mar; 3(9):1575-82. PubMed ID: 8507813
[TBL] [Abstract][Full Text] [Related]
7. Fetal renin-angiotensin-system blockade syndrome: renal lesions.
Plazanet C; Arrondel C; Chavant F; Gubler MC
Pediatr Nephrol; 2014 Jul; 29(7):1221-30. PubMed ID: 24477978
[TBL] [Abstract][Full Text] [Related]
8. Effect of ACE inhibition on the fetal kidney: decreased renal blood flow.
Martin RA; Jones KL; Mendoza A; Barr M; Benirschke K
Teratology; 1992 Oct; 46(4):317-21. PubMed ID: 1412062
[TBL] [Abstract][Full Text] [Related]
9. A role for the extracellular matrix component hyaluronan in kidney dysfunction during ACE-inhibitor fetopathy.
Hansell P; Palm F
Acta Physiol (Oxf); 2015 Apr; 213(4):795-804. PubMed ID: 25600777
[TBL] [Abstract][Full Text] [Related]
10. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review.
Bullo M; Tschumi S; Bucher BS; Bianchetti MG; Simonetti GD
Hypertension; 2012 Aug; 60(2):444-50. PubMed ID: 22753220
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin-II receptor 1 antagonist fetopathy--risk assessment, critical time period and vena cava thrombosis as a possible new feature.
Oppermann M; Padberg S; Kayser A; Weber-Schoendorfer C; Schaefer C
Br J Clin Pharmacol; 2013 Mar; 75(3):822-30. PubMed ID: 22816796
[TBL] [Abstract][Full Text] [Related]
12. ACE inhibitor fetopathy: a case series and survey of opinion amongst New Zealand paediatricians, obstetricians, neonatologists, and nephrologists.
Deva M; Kara T
N Z Med J; 2012 Sep; 125(1361):51-61. PubMed ID: 22960716
[TBL] [Abstract][Full Text] [Related]
13. Renin Angiotensin System Blocker Fetopathy: A Midwest Pediatric Nephrology Consortium Report.
Nadeem S; Hashmat S; Defreitas MJ; Westreich KD; Shatat IF; Selewski DT; Onder AM; Chiang M; Weaver DJ; Steinke J; Barcia J; Hernandez J; Hidalgo G; Ingraham SE; Abitbol CL; Pan C; Greenbaum LA
J Pediatr; 2015 Oct; 167(4):881-5. PubMed ID: 26130112
[TBL] [Abstract][Full Text] [Related]
14. [Fetopathy associated with exposure to angiotensin converting enzyme inhibitors].
Neves S; Santos R; Gomes C; Correia AJ
Acta Med Port; 2010; 23(4):697-700. PubMed ID: 20687999
[TBL] [Abstract][Full Text] [Related]
15. Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy--United States, Canada, and Israel, 1987-1995.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1997 Mar; 46(11):240-2. PubMed ID: 9082178
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin-converting enzyme inhibitor fetopathy: long-term outcome.
Laube GF; Kemper MJ; Schubiger G; Neuhaus TJ
Arch Dis Child Fetal Neonatal Ed; 2007 Sep; 92(5):F402-3. PubMed ID: 17284475
[TBL] [Abstract][Full Text] [Related]
17. Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers.
Walfisch A; Al-maawali A; Moretti ME; Nickel C; Koren G
J Obstet Gynaecol; 2011 Aug; 31(6):465-72. PubMed ID: 21823839
[TBL] [Abstract][Full Text] [Related]
18. User of angiotensin-converting-enzyme inhibitor and/or angiotensin II receptor blocker might be associated with vascular calcification in predialysis chronic kidney disease patients: a retrospective single-center observational study : ACEI/ARB and vascular calcification.
Takaori K; Iwatani H; Yamato M; Ito T
BMC Nephrol; 2021 Jan; 22(1):7. PubMed ID: 33407242
[TBL] [Abstract][Full Text] [Related]
19. The effects of chronic usage of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on contrast-induced nephropathy in low-risk patients [corrected].
Barış N; Özpelit E; Doğan NB; Kangül H; Gül S; Akdeniz B; Güneri S
Anadolu Kardiyol Derg; 2013 May; 13(3):245-50. PubMed ID: 23261803
[TBL] [Abstract][Full Text] [Related]
20. Neonatal hemochromatosis, renal tubular dysgenesis, and hypocalvaria in a neonate.
Johal JS; Thorp JW; Oyer CE
Pediatr Dev Pathol; 1998; 1(5):433-7. PubMed ID: 9688768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
